News from boehringer ingelheim pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Oct 10, 2019, 08:30 ET FDA Grants Ofev® Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to Ofev® (nintedanib), ...


Sep 30, 2019, 08:00 ET INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases

Boehringer Ingelheim announced today that in the Phase III INBUILD® trial Ofev® (nintedanib) slowed lung function decline by 57% across the overall...


Aug 05, 2019, 08:00 ET Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

Boehringer Ingelheim today announced updated, interim analysis results from the GioTag study, showing that initiating treatment with afatinib...


Jul 25, 2019, 18:37 ET FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

Boehringer Ingelheim today announced that the FDA's Arthritis Advisory Committee recommended (10-7 vote) to approve Ofev® (nintedanib) for the...


Jul 08, 2019, 23:27 ET New data show efficacy and safety of Pradaxa® in the management of VTE in children

Boehringer Ingelheim today announced results from two pediatric studies of Pradaxa®, which were presented at the International Society on Thrombosis...


May 20, 2019, 12:05 ET Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital...


May 14, 2019, 08:35 ET Boehringer Ingelheim announces resolution of Cyltezo® patent litigation

Boehringer Ingelheim today announced the resolution of all intellectual property-related litigation with AbbVie concerning Cyltezo® (adalimumab-adbm) ...


Mar 18, 2019, 08:00 ET Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease...


Oct 22, 2018, 09:14 ET Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced results from GioTag, a real-world retrospective, observational study, which assessed total treatment duration of ...


Oct 11, 2018, 08:00 ET FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) approved new labeling for Stiolto Respimat (tiotropium bromide...


Sep 26, 2018, 09:00 ET Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information ...


Sep 17, 2018, 08:00 ET New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

Results from INPULSIS-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy and tolerability of...


Mar 29, 2018, 08:00 ET New Large-Scale Trial Results Show Stiolto® Respimat® Prevents COPD Exacerbations Better Than Spiriva® Respimat®

Boehringer Ingelheim announced today that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range of COPD ...


Mar 19, 2018, 08:00 ET FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the...


Mar 13, 2018, 09:00 ET Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Boehringer Ingelheim and Vanderbilt University today announced the expansion of their successful existing collaboration to develop novel anti-cancer...


Jan 25, 2018, 10:12 ET New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

Boehringer Ingelheim today announced results from a retrospective, observational real-world study assessing the safety and effectiveness of novel...


Jan 16, 2018, 08:00 ET FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for...


Dec 12, 2017, 07:00 ET Boehringer Ingelheim initiates real-world study of treatment sequencing in EGFR mutation-positive lung cancer

Boehringer Ingelheim has initiated GioTag, a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive...


Nov 13, 2017, 19:30 ET New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

Boehringer Ingelheim today announced results from two new analyses of the phase III RE-VERSE AD™ study, which evaluated the safety and efficacy of...


Oct 23, 2017, 09:00 ET Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

Boehringer Ingelheim announced today the presentation of a new analysis on the use of Ofev® (nintedanib) in treating people with idiopathic pulmonary ...


Oct 10, 2017, 09:00 ET FDA grants Priority Review to Gilotrif® for uncommon EGFR mutations in advanced NSCLC

Boehringer Ingelheim today announced that the supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) has been accepted for filing and...


Sep 11, 2017, 09:30 ET Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Results from the INJOURNEY™ trial, investigating the use of Ofev® (nintedanib) in combination with pirfenidone in treating idiopathic pulmonary...


Jul 11, 2017, 08:00 ET Final Phase III Study Results Reinforces Safety and Efficacy of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations

Boehringer Ingelheim today announced final results from RE-VERSE AD™. The study shows that idarucizumab, marketed in the U.S. as Praxbind®, was able...


May 24, 2017, 07:00 ET IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the presentation of new analyses on the use of Ofev® (nintedanib) in treating idiopathic...


May 23, 2017, 08:00 ET New Analyses Show SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Improves Breathing for People with Asthma Regardless of BMI or Allergic Status

Boehringer Ingelheim today announced new analyses that provide further evidence that adding SPIRIVA RESPIMAT improved breathing across diverse...